File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C

TitleA case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C
Authors
KeywordsHBV genotype Ba, Bj, C
Lamivudine
Resistant mutation
Response to therapy
Issue Date2006
PublisherBlackwell Publishing Ltd.
Citation
Hepatology Research, 2006, v. 35 n. 2, p. 127-134 How to Cite?
AbstractBackground/aims: In eastern Asian countries, hepatitis B virus (HBV) genotype Ba (HBV/Ba), HBV/Bj and HBV/C are prevalent. The aim was to investigate the response or resistance to lamivudine therapy among patients with different HBV genotypes. Methods: Of 67 Japanese and Chinese patients with chronic hepatitis B, 18 patients with HBV/Bj, 15 with HBV/Ba and 34 with HBV/C were selected for a case-control study matched according to gender and age. All the patients were treated with lamivudine for 2 years and evaluated the response or emergence of the YMDD mutation at year 2 during the treatment. HBV genotypes were detected by the restriction fragment length polymorphism. The YMDD mutation was detected by the direct sequencing after amplification by PCR. Results: At year 2 during therapy, 44.8% of the patients showed normalization of ALT and undetectable HBV DNA (favorable response), 35.8% developed the YMDD mutation. There was no significant difference of response to the therapy among the three genotype groups. The emergence of the YMDD mutation was associated with HBV/C. By the multiple logistic regression analysis, however, the significant factor of a favorable response was a higher pretreatment ALT level and negative HBeAg status and the significant factor of the emergence of the YMDD mutation was HBV/C. Conclusions: Higher pretreatment ALT level, HBeAg status or HBV genotype may affect the response or resistance to lamivudine therapy. © 2006 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/77954
ISSN
2015 Impact Factor: 2.208
2015 SCImago Journal Rankings: 0.782
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorOrito, Een_HK
dc.contributor.authorFujiwara, Ken_HK
dc.contributor.authorTanaka, Yen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorKato, Ten_HK
dc.contributor.authorSugauchi, Fen_HK
dc.contributor.authorKusakabe, Aen_HK
dc.contributor.authorSata, Men_HK
dc.contributor.authorOkanoue, Ten_HK
dc.contributor.authorNiitsuma, Hen_HK
dc.contributor.authorSakugawa, Hen_HK
dc.contributor.authorHasegawa, Ien_HK
dc.contributor.authorMizokami, Men_HK
dc.date.accessioned2010-09-06T07:37:34Z-
dc.date.available2010-09-06T07:37:34Z-
dc.date.issued2006en_HK
dc.identifier.citationHepatology Research, 2006, v. 35 n. 2, p. 127-134en_HK
dc.identifier.issn1386-6346en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77954-
dc.description.abstractBackground/aims: In eastern Asian countries, hepatitis B virus (HBV) genotype Ba (HBV/Ba), HBV/Bj and HBV/C are prevalent. The aim was to investigate the response or resistance to lamivudine therapy among patients with different HBV genotypes. Methods: Of 67 Japanese and Chinese patients with chronic hepatitis B, 18 patients with HBV/Bj, 15 with HBV/Ba and 34 with HBV/C were selected for a case-control study matched according to gender and age. All the patients were treated with lamivudine for 2 years and evaluated the response or emergence of the YMDD mutation at year 2 during the treatment. HBV genotypes were detected by the restriction fragment length polymorphism. The YMDD mutation was detected by the direct sequencing after amplification by PCR. Results: At year 2 during therapy, 44.8% of the patients showed normalization of ALT and undetectable HBV DNA (favorable response), 35.8% developed the YMDD mutation. There was no significant difference of response to the therapy among the three genotype groups. The emergence of the YMDD mutation was associated with HBV/C. By the multiple logistic regression analysis, however, the significant factor of a favorable response was a higher pretreatment ALT level and negative HBeAg status and the significant factor of the emergence of the YMDD mutation was HBV/C. Conclusions: Higher pretreatment ALT level, HBeAg status or HBV genotype may affect the response or resistance to lamivudine therapy. © 2006 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd.en_HK
dc.relation.ispartofHepatology Researchen_HK
dc.rightsHepatology Research. Copyright © Blackwell Publishing Ltd.en_HK
dc.subjectHBV genotype Ba, Bj, Cen_HK
dc.subjectLamivudineen_HK
dc.subjectResistant mutationen_HK
dc.subjectResponse to therapyen_HK
dc.titleA case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and Cen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1386-6346&volume=35&spage=127&epage=134&date=2006&atitle=A+case-control+study+of+response+to+lamivudine+therapy+for+2+years+in+Japanese+and+Chinese+patients+chronically+infected+with+hepatitis+B+virus+of+genotypes+Bj,+Ba+and+Cen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.hepres.2006.03.005en_HK
dc.identifier.scopuseid_2-s2.0-33646801638en_HK
dc.identifier.hkuros121892en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646801638&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume35en_HK
dc.identifier.issue2en_HK
dc.identifier.spage127en_HK
dc.identifier.epage134en_HK
dc.identifier.isiWOS:000238585800009-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridOrito, E=7006161634en_HK
dc.identifier.scopusauthoridFujiwara, K=7403468620en_HK
dc.identifier.scopusauthoridTanaka, Y=7405315865en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridKato, T=7405277868en_HK
dc.identifier.scopusauthoridSugauchi, F=7004837927en_HK
dc.identifier.scopusauthoridKusakabe, A=13608375400en_HK
dc.identifier.scopusauthoridSata, M=35355942700en_HK
dc.identifier.scopusauthoridOkanoue, T=7101962104en_HK
dc.identifier.scopusauthoridNiitsuma, H=7006500814en_HK
dc.identifier.scopusauthoridSakugawa, H=7006875192en_HK
dc.identifier.scopusauthoridHasegawa, I=7101889902en_HK
dc.identifier.scopusauthoridMizokami, M=7103318255en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats